PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB – Get a Free Report)Its stock was restated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $21.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 486.59% from the company’s previous close.

PDSB has been the subject of a number of other research reports. B. Riley cut their price target on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, June 12th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Moderate Buy” and an average price target of $14.25, according to MarketBeat.com.

See our latest report on PDS biotech

PDS Biotechnology price performance

Shares of PDS Biotechnology stock traded up $0.07 on Wednesday, reaching $3.58. The company’s stock had a trading volume of 351,640 shares, compared to its average volume of 638,744. The company has a quick ratio of 3.84, a current ratio of 3.84, and a debt-to-equity ratio of 0.45. The firm has a fifty day moving average price of $3.24 and a 200 day moving average price of $3.35. PDS Biotechnology has a 52 week low of $2.53 and a 52 week high of $6.85. The company has a market cap of $131.31 million, a P/E ratio of -2.63 and a beta of 1.88.

PDS Biotechnology (NASDAQ:PDSB – Get Free Report ) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same period last year, the firm posted ($0.37) EPS. On average, equities research analysts expect that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

Institutional commercialization of PDS Biotechnology

A number of institutional investors have recently modified their holdings of the company. Inspirion Wealth Advisors LLC grew its stake in PDS Biotechnology by 1.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after buying an additional 4,917 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in PDS Biotechnology in the first quarter worth $28,000. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology in the second quarter valued at $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology in the second quarter valued at about $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology in the second quarter worth about $115,000. Hedge funds and other institutional investors own 26.84% of the company’s shares.

About PDS Biotechnology

(Get a free report)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company developing a pipeline of cancer immunotherapies in the United States. The company’s lead product candidate PDS0101 (HPV16), which is in Phase II clinical trial, provides first-line treatment for recurrent/metastatic head and neck cancer and human papillomavirus-associated malignancies.

Featured stories

Get news and reviews for PDS Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PDS Biotechnology and related companies with MarketBeat.com ‘s FREE daily email newsletter.